Quinn Tyler, Cholette Jill M, Pinto Matthew G, Schreiber Hilary, Madden Maureen A, Bennett Erin, Kolmar Amanda, Poole Alan, Silva Cicero T, Ehrlich Lauren, Navarro Oscar M, Faustino E Vincent S
Pediatric Intensive Care Unit, Yale-New Haven Children's Hospital, New Haven, Connecticut, USA.
Department of Pediatrics, University of Rochester Golisano Children's Hospital, Rochester, New York, USA.
J Thromb Haemost. 2024 Jan;22(1):213-224. doi: 10.1016/j.jtha.2023.09.023. Epub 2023 Oct 4.
Normalization of antithrombin activity may prevent catheter-associated thrombosis in critically ill children at high risk of bleeding.
To characterize the temporal pattern of antithrombin activity, assess its association with catheter-associated thrombosis and clinically relevant bleeding, and evaluate its relationship with thrombin generation in these children.
In this prospective cohort study, critically ill children <18 years old at high risk of bleeding with central venous catheter were eligible. Antithrombin activity and thrombin generation were measured from platelet-poor plasma and after in vitro antithrombin supplementation. Systematic surveillance ultrasound was performed to diagnose thrombosis. Children were followed for bleeding.
We enrolled 8 infants (median age: 0.2 years, IQR: 0.2, 0.3 years) and 72 older children (median age: 14.3 years, IQR: 9.1, 16.1 years). Mean antithrombin on the day of catheter insertion was 64 IU/dL (SD: 32 IU/dL) in infants and 83 IU/dL (SD: 35 IU/dL) in older children. Antithrombin normalized by the day of catheter removal. Thrombosis developed in 27 children, while 31 children bled. Thrombosis (regression coefficient: 0.008, 95% CI: -0.01, 0.03) and bleeding (regression coefficient: -0.0007, 95% CI: -0.02, 0.02) were not associated with antithrombin. Antithrombin was not correlated with in vivo change in endogenous thrombin potential (correlation coefficient: -0.07, 95% CI: -0.21, 0.08). In vitro supplementation reduced endogenous thrombin potential (correlation coefficient: -0.78; 95% CI: -0.95, -0.23).
These findings may not support normalization of antithrombin activity to prevent catheter-associated thrombosis in critically ill children at high risk of bleeding.
对于有高出血风险的危重症儿童,抗凝血酶活性正常化可能预防导管相关血栓形成。
描述抗凝血酶活性的时间模式,评估其与导管相关血栓形成及临床相关出血的关联,并评估其与这些儿童凝血酶生成的关系。
在这项前瞻性队列研究中,纳入年龄小于18岁、有中心静脉导管且有高出血风险的危重症儿童。从乏血小板血浆中以及体外补充抗凝血酶后测量抗凝血酶活性和凝血酶生成。进行系统性超声监测以诊断血栓形成。对儿童进行出血情况随访。
我们纳入了8名婴儿(中位年龄:0.2岁,四分位间距:0.2,0.3岁)和72名大龄儿童(中位年龄:14.3岁,四分位间距:9.1,16.1岁)。导管插入当天婴儿的平均抗凝血酶水平为64 IU/dL(标准差:32 IU/dL),大龄儿童为83 IU/dL(标准差:35 IU/dL)。到导管拔除当天抗凝血酶活性恢复正常。27名儿童发生血栓形成,31名儿童出现出血。血栓形成(回归系数:0.008,95%置信区间:-0.01,0.03)和出血(回归系数:-0.0007,95%置信区间:-0.02,0.02)与抗凝血酶无关。抗凝血酶与内源性凝血酶潜力的体内变化无相关性(相关系数:-0.07,95%置信区间:-0.21,0.08)。体外补充抗凝血酶降低了内源性凝血酶潜力(相关系数:-0.78;95%置信区间:-0.95,-0.23)。
这些发现可能不支持通过使抗凝血酶活性正常化来预防有高出血风险的危重症儿童的导管相关血栓形成。